Drug-Induced Liver Injury: Pathogenesis to Treatment Options
Comprehensive Lecture Summary
1. Main Clinical Topics Discussed
- Definition and scope of idiosyncratic drug-induced liver injury (DILI)
- Risk factors for DILI: drug-related, host-related, and environmental
- Pathogenetic mechanisms underlying DILI in humans
- Role of genetic polymorphisms and immune mechanisms
- Pharmacogenomics and genome-wide association studies (GWAS) in DILI
2. Key Learning Points, Guidelines, and Recommendations
Definition and Scope
- Focus is on acute liver injury caused by medications taken at therapeutic doses
- Injury is not fully explained by the pharmacological action of the drug
- Termed *idiosyncratic* DILI to distinguish from dose-dependent (intrinsic) toxicity
- Idiosyncratic DILI is typically only identified after a drug enters widespread clinical use, as animal models poorly predict individual human susceptibility
Risk Factor Framework (Drug–Host–Environment Triangle)
*Drug-related factors:*
- Daily dose within therapeutic range is a significant risk modifier
- Hepatic metabolism and biliary excretion consistently associated with hepatotoxic potential
- Drugs with >50% hepatic metabolism carry significantly higher risk of liver enzyme elevation, liver failure, and death
*Environmental factors:*
- Pre-existing fatty liver disease / chronic liver disease increases susceptibility to DILI (see statistics below)
*Host factors:*
- Age and ethnicity are contributory
- Genetic polymorphisms are the most clinically significant host factors and cannot be replicated reliably in animal models
Pathogenetic Pathway (Diclofenac as a Model Drug)
- Most drugs form reactive metabolites as minor metabolic by-products
- Normally, reactive metabolites are bio-inactivated and excreted safely
- In susceptible individuals, genetic variants alter metabolic enzyme activity or transporter function, leading to accumulation of reactive metabolites
- Accumulated reactive metabolites may:
- Bind to cellular proteins, forming covalent adducts → cellular dysfunction
- Bind to circulating proteins → systemic adduct formation
- Be presented via HLA molecules → adaptive immune activation
- The "Danger Hypothesis": the immune system responds not to self/non-self distinction, but to danger signals released during subclinical liver injury (cytokines, chemokines, DAMPs), potentially triggering an amplified immune response
3. Specific Clinical Data, Statistics, and Study Results
- Pharma candidate drug analysis (77 drugs): The liver was the most common target organ for toxicity, accounting for approximately two-thirds of all organ toxicities in both rodent and non-rodent models; 72% of drugs showing hepatotoxicity signals were still advanced to the next development stage, reflecting poor confidence in animal model predictive validity
- Daily dose and DILI risk (230 top U.S. generic drugs): Drugs with daily therapeutic doses >50 mg/day were associated with:
- Significantly higher reports of jaundice
- Higher risk of liver failure
- Increased risk of death and need for transplantation
- Compared to drugs dosed at <10 mg/day or 10–49 mg/day
- Fatty liver disease and DILI susceptibility (U.S. database cohort, ~5,000 patients):
- Incidence of DILI was fourfold higher in patients with fatty liver disease compared to both control groups
- No significant difference in severity or outcome of DILI was demonstrated in this fatty liver cohort
- Diclofenac pharmacogenomics (candidate gene study):
- Polymorphisms in UGT2B7 (overactive variant): 8.5-fold increased likelihood of diclofenac hepatotoxicity
- Polymorphisms in ABCC2 transporter (underactive variant): fivefold increased risk of hepatotoxicity
- Diclofenac-related antibodies detected in serum of cases, confirming adduct formation in vivo
- Polymorphisms in **IL